

AmpliPhi Biosciences Corp
Form 3/A
February 24, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *	2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol
Â WILLIAMS GWYNN	(Month/Day/Year)	AmpliPhi Biosciences Corp [APHB]
(Last) (First) (Middle)	02/18/2014	
BALLCARRICK, POOILVASSISH ROAD		4. Relationship of Reporting Person(s) to Issuer
(Street)		(Check all applicable)
		_____ Director _____ 10% Owner
		_____ Officer _____ Other
		(give title below) (specify below)
CASTLETOWN,Â Y8Â IM9 4PJ		5. If Amendment, Date Original Filed(Month/Day/Year)
(City) (State) (Zip)		02/18/2014
		6. Individual or Joint/Group Filing(Check Applicable Line)
		__X__ Form filed by One Reporting Person
		___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of Shares			

(Instr. 5)

Series B Convertible Preferred Stock	06/26/2013	Â ⁽¹⁾	Common Stock	32,250,610	\$ ⁽²⁾	I	By Pendinas Limited ⁽³⁾
Warrant (right to buy)	02/04/2013	02/04/2018	Common Stock	4,351,816	\$ 0.14	I	By Pendinas Limited ⁽³⁾
Warrant (right to buy)	03/12/2013	03/04/2018	Common Stock	892,857	\$ 0.14	I	By Pendinas Limited ⁽³⁾
Warrant (right to buy)	04/12/2013	04/12/2018	Common Stock	892,857	\$ 0.14	I	By Pendinas Limited ⁽³⁾
Warrant (right to buy)	05/13/2013	05/13/2018	Common Stock	892,857	\$ 0.14	I	By Pendinas Limited ⁽³⁾
Warrant (right to buy)	06/26/2013	06/26/2018	Common Stock	8,062,652	\$ 0.14	I	By Pendinas Limited ⁽³⁾

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

WILLIAMS GWYNN
 BALLCARRICK, POOILVASSISH ROAD Â Â X Â Â
 CASTLETOWN,Â Y8Â IM9 4PJ

Signatures

/s/ Gwynn
 Williams 02/24/2014

⁽¹⁾Signature of
 Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

(2) Pursuant to its terms, each share of Series B Convertible Preferred Stock is convertible into ten (10) shares of Common Stock.

Gwynn Williams controls Pendinas Limited. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Act of 1934, as amended) by Mr. Williams. Mr. Williams disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.